A5036297052- Diabetes Treatment and Management
- Diabetes Management and Research
- COVID-19 Clinical Research Studies
- Diabetes and associated disorders
- Chronic Kidney Disease and Diabetes
- Pharmacology and Obesity Treatment
- Metabolism, Diabetes, and Cancer
- Diet and metabolism studies
- Pancreatic function and diabetes
- Hormonal Regulation and Hypertension
- Blood Pressure and Hypertension Studies
- Apelin-related biomedical research
- Potassium and Related Disorders
- Pituitary Gland Disorders and Treatments
- COVID-19 and healthcare impacts
- Cardiovascular Function and Risk Factors
- Chronic Disease Management Strategies
- Peroxisome Proliferator-Activated Receptors
- Cholesterol and Lipid Metabolism
- Long-Term Effects of COVID-19
- Bone health and treatments
- Diabetes Management and Education
- Vitamin D Research Studies
- Balance, Gait, and Falls Prevention
- Dietary Effects on Health
University at Buffalo, State University of New York
2018-2025
University College London
2013-2025
The Royal Free Hospital
2015-2025
Royal Free London NHS Foundation Trust
2018-2024
Roland Hill (United Kingdom)
2022
St. George's University
2021
Emory University
2020
Association of British Clinical Diabetologists
2020
Guy's and St Thomas' NHS Foundation Trust
2020
Medical University of Lublin
2019
Abstract People with type 1 and 2 diabetes are at risk of developing progressive chronic kidney disease (CKD) end-stage failure. Hypertension is a major, reversible factor in people for development albuminuria, impaired function, cardiovascular disease. Blood pressure control has been shown to be beneficial slowing progression reducing events. However, randomised controlled trial evidence differs different stages CKD terms target blood pressure. Activation the renin-angiotensin-aldosterone...
Objective Increasing plasma glucose levels are associated with increasing risk of vascular disease. We tested the hypothesis that there is a glycaemia-mediated impairment reverse cholesterol transport (RCT). studied influence on expression and function key mediator in RCT, ATP binding cassette transporter-A1 (ABCA1) its regulators, liver X receptor-α (LXRα) peroxisome proliferator-activated receptor–γ (PPARγ). Methods Results Leukocyte ABCA1, LXRα PPARγ was measured by polymerase chain...
Use of supraglottic airways by emergency medical services (EMS) clinicians has increased for patients all ages. However, data are limited on real-world use in the prehospital setting, including success rates, complications, and paramedic experience. The objective this study was to determine frequency successful i-gel® insertion associated describe perception use. This a prospective adult at four fire-based EMS Provider Agencies Los Angeles (LA) County from June September 2021. All paramedics...
A significant percentage of people with diabetes develop chronic kidney disease and is also a leading cause end-stage (ESKD). The term diabetic (DKD) includes both nephropathy (DN) mellitus (DM CKD). DKD associated high morbidity mortality, which are predominantly related to cardiovascular disease. Hyperglycaemia modifiable risk factor for complications progression DKD. Recent clinical trials have demonstrated improvement in outcomes sodium glucose co-transporter-2 (SGLT-2) inhibitors....
To determine the association between prescription of SGLT2 inhibitors (SGLT2is) and diabetic ketoacidosis (DKA) incidence or mortality in people with type 2 diabetes (T2D) hospitalized COVID-19.
The health of the United Kingdom workforce is key; approximately 186 million days are lost to sickness each year. Obesity and type 2 diabetes (T2D) remain major global challenges. aim this retrospective service evaluation was assess impact a digitally enabled, time-restricted eating (TRE) intervention (Roczen Program, Reset Health Ltd) on weight other health-related outcomes.
Oral profiles of head and neck cancer patients vary substantially, for this reason dental protocols should be tailored accordingly.
<h3>ABSTRACT</h3> Sodium glucose co-transporter 2 (SGLT2) inhibitors are now an established class of medications for the treatment type diabetes (T2D), no longer reserved use by specialists in diabetes. They being used increasingly their cardiac and renal benefits primary care, cardiology teams indications parallel with care as part holistic management. This guidance provides essential information on SGLT therapy, including main advantages important risks which healthcare professionals...